Cargando…

In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease

BACKGROUND: We investigated regional amyloid staging characteristics in (11)C-PiB-PET data from middle-aged to older participants at elevated risk for AD enrolled in the Wisconsin Registry for Alzheimer’s Prevention. METHODS: We analyzed partial volume effect-corrected (11)C-PiB-PET distribution vol...

Descripción completa

Detalles Bibliográficos
Autores principales: Levin, Fedor, Jelistratova, Irina, Betthauser, Tobey J., Okonkwo, Ozioma, Johnson, Sterling C., Teipel, Stefan J., Grothe, Michel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532333/
https://www.ncbi.nlm.nih.gov/pubmed/34674764
http://dx.doi.org/10.1186/s13195-021-00918-0
_version_ 1784587046204997632
author Levin, Fedor
Jelistratova, Irina
Betthauser, Tobey J.
Okonkwo, Ozioma
Johnson, Sterling C.
Teipel, Stefan J.
Grothe, Michel J.
author_facet Levin, Fedor
Jelistratova, Irina
Betthauser, Tobey J.
Okonkwo, Ozioma
Johnson, Sterling C.
Teipel, Stefan J.
Grothe, Michel J.
author_sort Levin, Fedor
collection PubMed
description BACKGROUND: We investigated regional amyloid staging characteristics in (11)C-PiB-PET data from middle-aged to older participants at elevated risk for AD enrolled in the Wisconsin Registry for Alzheimer’s Prevention. METHODS: We analyzed partial volume effect-corrected (11)C-PiB-PET distribution volume ratio maps from 220 participants (mean age = 61.4 years, range 46.9–76.8 years). Regional amyloid positivity was established using region-specific thresholds. We used four stages from the frequency-based staging of amyloid positivity to characterize individual amyloid deposition. Longitudinal PET data was used to assess the temporal progression of stages and to evaluate the emergence of regional amyloid positivity in participants who were amyloid-negative at baseline. We also assessed the effect of amyloid stage on longitudinal cognitive trajectories. RESULTS: The staging model suggested progressive accumulation of amyloid from associative to primary neocortex and gradually involving subcortical regions. Longitudinal PET measurements supported the cross-sectionally estimated amyloid progression. In mixed-effects longitudinal analysis of cognitive follow-up data obtained over an average period of 6.5 years following the baseline PET measurement, amyloid stage II showed a faster decline in executive function, and advanced amyloid stages (III and IV) showed a faster decline across multiple cognitive domains compared to stage 0. CONCLUSIONS: Overall, the (11)C-PiB-PET-based staging model was generally consistent with previously derived models from (18)F-labeled amyloid PET scans and a longitudinal course of amyloid accumulation. Differences in longitudinal cognitive decline support the potential clinical utility of in vivo amyloid staging for risk stratification of the preclinical phase of AD even in middle-aged to older individuals at risk for AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00918-0.
format Online
Article
Text
id pubmed-8532333
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85323332021-10-25 In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease Levin, Fedor Jelistratova, Irina Betthauser, Tobey J. Okonkwo, Ozioma Johnson, Sterling C. Teipel, Stefan J. Grothe, Michel J. Alzheimers Res Ther Research BACKGROUND: We investigated regional amyloid staging characteristics in (11)C-PiB-PET data from middle-aged to older participants at elevated risk for AD enrolled in the Wisconsin Registry for Alzheimer’s Prevention. METHODS: We analyzed partial volume effect-corrected (11)C-PiB-PET distribution volume ratio maps from 220 participants (mean age = 61.4 years, range 46.9–76.8 years). Regional amyloid positivity was established using region-specific thresholds. We used four stages from the frequency-based staging of amyloid positivity to characterize individual amyloid deposition. Longitudinal PET data was used to assess the temporal progression of stages and to evaluate the emergence of regional amyloid positivity in participants who were amyloid-negative at baseline. We also assessed the effect of amyloid stage on longitudinal cognitive trajectories. RESULTS: The staging model suggested progressive accumulation of amyloid from associative to primary neocortex and gradually involving subcortical regions. Longitudinal PET measurements supported the cross-sectionally estimated amyloid progression. In mixed-effects longitudinal analysis of cognitive follow-up data obtained over an average period of 6.5 years following the baseline PET measurement, amyloid stage II showed a faster decline in executive function, and advanced amyloid stages (III and IV) showed a faster decline across multiple cognitive domains compared to stage 0. CONCLUSIONS: Overall, the (11)C-PiB-PET-based staging model was generally consistent with previously derived models from (18)F-labeled amyloid PET scans and a longitudinal course of amyloid accumulation. Differences in longitudinal cognitive decline support the potential clinical utility of in vivo amyloid staging for risk stratification of the preclinical phase of AD even in middle-aged to older individuals at risk for AD. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-021-00918-0. BioMed Central 2021-10-21 /pmc/articles/PMC8532333/ /pubmed/34674764 http://dx.doi.org/10.1186/s13195-021-00918-0 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Levin, Fedor
Jelistratova, Irina
Betthauser, Tobey J.
Okonkwo, Ozioma
Johnson, Sterling C.
Teipel, Stefan J.
Grothe, Michel J.
In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease
title In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease
title_full In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease
title_fullStr In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease
title_full_unstemmed In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease
title_short In vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of Alzheimer’s disease
title_sort in vivo staging of regional amyloid progression in healthy middle-aged to older people at risk of alzheimer’s disease
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8532333/
https://www.ncbi.nlm.nih.gov/pubmed/34674764
http://dx.doi.org/10.1186/s13195-021-00918-0
work_keys_str_mv AT levinfedor invivostagingofregionalamyloidprogressioninhealthymiddleagedtoolderpeopleatriskofalzheimersdisease
AT jelistratovairina invivostagingofregionalamyloidprogressioninhealthymiddleagedtoolderpeopleatriskofalzheimersdisease
AT betthausertobeyj invivostagingofregionalamyloidprogressioninhealthymiddleagedtoolderpeopleatriskofalzheimersdisease
AT okonkwoozioma invivostagingofregionalamyloidprogressioninhealthymiddleagedtoolderpeopleatriskofalzheimersdisease
AT johnsonsterlingc invivostagingofregionalamyloidprogressioninhealthymiddleagedtoolderpeopleatriskofalzheimersdisease
AT teipelstefanj invivostagingofregionalamyloidprogressioninhealthymiddleagedtoolderpeopleatriskofalzheimersdisease
AT grothemichelj invivostagingofregionalamyloidprogressioninhealthymiddleagedtoolderpeopleatriskofalzheimersdisease